Objective: To explore contraceptive decision making among recently pregnant patients with a history of opioid use disorder.
Study Design: We conducted semi-structured qualitative interviews, based on principles of the Ottawa Decision Support Framework, with 20 recently pregnant individuals diagnosed with opioid use disorder at a tertiary care medical center in Massachusetts. We audio-recorded the interviews and they were transcribed verbatim. We analyzed our interview data using inductive and deductive coding.
Results: Participants value the availability of barrier methods as a means of preventing both sexually transmitted infections and pregnancy. For some participants, housing instability makes storing contraceptive methods and managing personal hygiene related to bleeding patterns difficult. For others, housing instability impacts their overall fertility goals. Side effects including weight gain, interactions with mood stabilizing medications, concern regarding post-operative opioids, or intrinsic aspects of a method that serve as reminders of opioid use may be unacceptable given the risk of relapse. The relapsing and remitting arc of recovery make remembering important aspects of both short- and long-acting contraceptive method use difficult, yet participants offer strategies to aid in doing so.
Conclusion: When choosing a contraceptive method participants in our study exhibit similarities to individuals with other chronic medical conditions as well as motivations specific to opioid use disorder. Their contraceptive decisions are grounded in integrating a method into a chaotic life, preventing relapse, and protecting future fertility.
Implications: Our data highlight how lived experiences at the intersection of active opioid use disorder and recovery fundamentally shape the lens through which pregnancy-capable individuals with opioid use disorder view their contraceptive decisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2021.06.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of Participation in Prenatal Substance Use Assessment, Counseling, and Treatment Among Pregnant Individuals in Prenatal Settings Who Use Cannabis.
J Addict Med
November 2024
From the, Kaiser Permanente Washington Health Research Institute, Seattle, WA (GTL); Department of Health Systems and Population Health, University of Washington, Seattle, WA (GTL); Division of Research, Kaiser Permanente Northern California, Oakland, CA (FWC, KCY-W, MBD, CIC); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA (KCY-W, CIC); and Regional Offices, Kaiser Permanente Northern California, Oakland CA (DA, CC, AHA, AE).
Objectives: Assessment and counseling are recommended for individuals with prenatal cannabis use. We examined characteristics that predict prenatal substance use assessment and counseling among individuals who screened positive for prenatal cannabis use in prenatal settings.
Methods: Electronic health record data from Kaiser Permanente Northern California's Early Start perinatal substance use screening, assessment, and counseling program was used to identify individuals with ≥1 pregnancies positive for prenatal cannabis use.
Substructure-Specific Antibodies Against Fentanyl Derivatives.
ACS Nano
January 2025
School of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Dr., Atlanta, Georgia 30332, United States.
Structural variants of the synthetic opioid fentanyl are a major threat to public health. Following an investigation showing that many derivatives are poorly detected by commercial lateral flow and related assays, we created hapten conjugate vaccines using an immunogenic virus-like particle carrier and eight synthetic fentanyl derivatives designed to mimic the structural features of several of the more dangerous analogues. Immunization of mice elicited strong antihapten humoral responses, allowing the screening of hundreds of hapten-specific hybridomas for binding strength and specificity.
View Article and Find Full Text PDFProspective evaluation of opioid cessation in patients with suspected Opioid-induced esophageal dysfunction (OIED).
Am J Gastroenterol
January 2025
Neurogastroenterology and Motility Unit, Gastroenterology Department, Institut Clínic de Malalties Digestives i Metabòliques (ICMDM), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain 08036.
Introduction: The causal relationship between chronic opioid use and esophageal motor dysfunction in symptomatic patients has not been established.
Methods: A prospective before-and-after multicenter study, including chronic active opioid patients referred for esophageal motility tests due to non-obstructive dysphagia.
Results: 37 patients were evaluated, 27 (73%) had criteria of opioid-induced esophageal dysfunction (OIED).
Sociodemographic and Clinical Profiles of Patients With Substance Use Disorders Admitted to a Psychiatric Hospital in Erbil: A Retrospective Study.
Cureus
December 2024
Department of Psychiatry, College of Medicine, Hawler Medical University, Erbil, IRQ.
Background: Substance use is a growing concern, impacting the health, social stability, and economic well-being of individuals and communities. In Iraq, particularly in Erbil, limited data exists on the sociodemographic and clinical characteristics of patients with substance use disorders (SUDs). This study aims to identify these characteristics among inpatients at Hawler Psychiatric Hospital to better understand the profiles and associated factors influencing substance use in this region.
View Article and Find Full Text PDFPatient Challenges in Utilization of Methadone to Treat Opioid Use Disorder and Perspectives on a Solution for Improved Security and Convenience in Take-home Dosing.
Innov Clin Neurosci
December 2024
Mr. Timberlake is with Berkshire Biomedical Corporation in Dallas, Texas.
Background: Methadone is commonly utilized to treat opioid use disorder (OUD). Requirements to visit an opioid treatment provider (OTP) clinic for methadone treatment limits access to treatment, impacts quality of life, and reduces OUD treatment program retention. The Computerized Oral Prescription Administration (COPA) system is a dual-biometric dispensing device for take-home dosing that could reduce the impacts of methadone administration on patients and clinic staff.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!